Scott A Bull

Summary

Affiliation: ALZA Corporation
Country: USA

Publications

  1. ncbi Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate
    X Henry Hu
    Outcomes Research and Management, Merck and Co, Inc, West Point, PA 19486, USA
    J Clin Psychiatry 65:959-65. 2004
  2. ncbi Discontinuation of use and switching of antidepressants: influence of patient-physician communication
    Scott A Bull
    Division of Research, Kaiser Permanente Medical Care Program, 2000 Broadway, Oakland, CA 94612 2304, USA
    JAMA 288:1403-9. 2002
  3. ncbi Discontinuing or switching selective serotonin-reuptake inhibitors
    Scott A Bull
    The Permanente Medical Group Division of Research, Kaiser Permanente, Oakland, CA, USA
    Ann Pharmacother 36:578-84. 2002
  4. ncbi Impact of a collaborative pharmacy practice model on the treatment of depression in primary care
    Patrick R Finley
    Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco (UCSF, San Francisco, USA
    Am J Health Syst Pharm 59:1518-26. 2002
  5. ncbi Impact of a collaborative care model on depression in a primary care setting: a randomized controlled trial
    Patrick R Finley
    Department of Clinical Pharmacy, University of California at San Francisco, San Francisco, California 94143 0622, USA
    Pharmacotherapy 23:1175-85. 2003
  6. ncbi Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine
    Ridwan Shabsigh
    Division of Urology, Maimonides Medical Center, Columbia University, New York, NY 11219, USA
    BJU Int 102:824-8. 2008

Collaborators

Detail Information

Publications6

  1. ncbi Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate
    X Henry Hu
    Outcomes Research and Management, Merck and Co, Inc, West Point, PA 19486, USA
    J Clin Psychiatry 65:959-65. 2004
    ..Selective serotonin reuptake inhibitors (SSRIs) are widely used as the first-line treatment for depression. Information regarding their side effects is mostly based on controlled clinical trials...
  2. ncbi Discontinuation of use and switching of antidepressants: influence of patient-physician communication
    Scott A Bull
    Division of Research, Kaiser Permanente Medical Care Program, 2000 Broadway, Oakland, CA 94612 2304, USA
    JAMA 288:1403-9. 2002
    ..Although current depression treatment guidelines recommend continuing antidepressant therapy for at least 4 to 9 months, many patients discontinue treatment prematurely, within 3 months...
  3. ncbi Discontinuing or switching selective serotonin-reuptake inhibitors
    Scott A Bull
    The Permanente Medical Group Division of Research, Kaiser Permanente, Oakland, CA, USA
    Ann Pharmacother 36:578-84. 2002
    ..Informing patients of potential adverse effects does not appear to prevent premature discontinuation, but may increase the patient's awareness and reporting of mild to moderate adverse effects...
  4. ncbi Impact of a collaborative pharmacy practice model on the treatment of depression in primary care
    Patrick R Finley
    Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco (UCSF, San Francisco, USA
    Am J Health Syst Pharm 59:1518-26. 2002
    ....
  5. ncbi Impact of a collaborative care model on depression in a primary care setting: a randomized controlled trial
    Patrick R Finley
    Department of Clinical Pharmacy, University of California at San Francisco, San Francisco, California 94143 0622, USA
    Pharmacotherapy 23:1175-85. 2003
    ..Clinical pharmacists had a favorable effect on multiple aspects of patient care. Future studies of this model in other health care settings appear warranted...
  6. ncbi Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine
    Ridwan Shabsigh
    Division of Urology, Maimonides Medical Center, Columbia University, New York, NY 11219, USA
    BJU Int 102:824-8. 2008
    ....